Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach

Journal of Hepatology

Volumn 34, Issue 4, 2001, Pages 593-602

  Cammà, Calogero ^a,d   Giunta, Marco ^b   Andreone, Pietro ^c   Crax, Antonio ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d NONE   (Italy)

Author keywords

Hepatocellular carcinoma; Interferon; Viral cirrhosis

Indexed keywords

RECOMBINANT INTERFERON;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC HETEROGENEITY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 0035061788     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00005-8     Document Type: Article

References (50)

1. Rising incidence of hepatocellular carcinoma in the United States
2. Long-term course of interferon-treated chomic hepatitis C
3. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
4. Hepatitis C virus infection in Italy: A multicentric sero-epidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver)
5. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study
6. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B
7. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
8. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
9. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
10. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis
11. Hepatitus C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
12. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
13. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
14. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
15. Inpact of interferon therapy on the natural history of HCV-related cirrhosis
16. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
17. Effect of lymphoblastoid IFN in the treatment of liver cirrhosis and prevention of HCC
18. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis
19. Long-term prognosis of hepatocellular carcinoma developing after treatment of interferon in patients with chronic hepatitis C and liver cirrhosis
20. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan
21. Five years follow-up after Interferon therapy in HCV-positive compensated cirrhosis
22. Treatment of hepatitis C virus-related cirrhosis: A randomized controlled trial of interferon alfa 2b versus no treatment
23. Long-term survival following treatment of hepatocellular carcinoma in Singapore
24. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
25. The long term course of chronic hepatitis B
26. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus
27. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
28. Long-term course of interferon-treated choruic hepatitis C
29. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection
30. Meta-analysis in clinical trials
31. Statistical aspects of the analysis of data from retrospective studies of disease
32. Reduction in fatal pulmonary embolism and venous thrombosis by peri-operative administration of subcutaneous heparin: Overview of results of randomized trials in general orthopedic and urologic surgery
33. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment
34. Inborn/outborn status and neonatal survival: A meta-analysis of non-randomized studies
35. Meta-analyses of randomized controlled trials
36. Randomized versus historical controls for clinical trials
37. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
38. Cohort studies. Selection bias in observational and experimental studies
39. Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response
40. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy)
41. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
42. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial
43. Anti-apoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
44. Wild-type, but not mutant-type, p53 enhances nuclear accumulation of the NS3 protein of hepatitis C vires
45. Transcriptional repression of p53 promoter by hepatitis C virus core protein
46. Activation of p53 tumor suppressor by hepatitis C virus core protein
47. Survey of hepatitis B virus co-infection in hepatitis C virus-infected patients suffering from chronic hepatitis and hepatocellular carcinoma in Japan